Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00128271 · ClinicalTrials.gov registry record · Phase 1
Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection
A Phase 1 study of Hepatitis C, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00128271: Completed Phase 1 study of Hepatitis C, sponsored by Peregrine Pharmaceuticals.
NCT00128271 is a Phase 1 study of Hepatitis C that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 32 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00128271, a Phase 1 study of Hepatitis C, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.
Conditions Studied
Interventions
- DRUG Bavituximab
Study Locations (1)
Florida
- Bach & Godofsky, MD, PA - Bradenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-08 |
| Phase | Phase 1 |
What the finished NCT00128271 record still lists
NCT00128271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Bavituximab is the first listed.
NCT00128271 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT00128271 about?
NCT00128271 is a clinical study titled "Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection". The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.
What is the current status of trial NCT00128271?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-08.
What conditions does trial NCT00128271 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00128271?
The interventions under investigation include: Bavituximab (DRUG).
Who is sponsoring clinical trial NCT00128271?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00128271 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00128271's enrollment target sits among peer trials
32 82nd of 106 higher than 25 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.
COMPLETED · Phase 1
-
Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-Infection
COMPLETED · Phase 1
-
Open-Label Hepatic Impairment Study
COMPLETED · Phase 1
-
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
COMPLETED · Phase 1
-
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
COMPLETED · Phase 1
-
GS-7977 With Ribavirin for Hepatitis C (SPARE)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia